Compare Navan Inc. Class A Common Stock (NAVN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Navan Inc. Class A Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? Navan Inc. Class A Common Stock trades at $23.63 (market cap $6.01B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Navan Inc. Class A Common Stock is far larger — about 2.8× Recursion Pharmaceuticals Inc's market cap, and Navan Inc. Class A Common Stock is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Navan Inc. Class A Common Stock for 1 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| NAVN | RXRX | |
|---|---|---|
Market Cap | $6.01B | $2.14B |
Volume | 2,990,425 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $30.58 | $6.79 |
52-Week Low | $8.51 | $2.84 |
Typical Hold Time | 1 Days | 23 Days |
Enterprise Value | $5.36B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Navan Inc. Class A Common Stock
Navan provides an AI-powered platform for business travel, payments, and expense management. Its tools support trip booking, policy controls, payment processing, expense reconciliation, and reporting.
Read more on NAVN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
